Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 460 of 5804
-
New combo therapy aims to wipe out prostate tumors before surgery
Disease control Recruiting nowThe high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with r…
Phase: PHASE2 • Sponsor: baotai Liang • Aim: Disease control
Last updated Jun 26, 2026 14:51 UTC
-
New Three-Drug cocktail aims to outsmart tough leukemia
Disease control Recruiting nowThis research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: …
Phase: PHASE1, PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug duo aims to keep ovarian cancer at bay longer
Disease control Recruiting nowThis clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo aims to tackle lymphoma that survives CAR-T
Disease control Recruiting nowThe purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Obesity drug may ignite 'Brown Fat' to torch calories
Disease control CompletedThis study is testing whether a new anti-obesity medicine called tirzepatide can increase the activity of special fat cells in the body that help burn energy. These fat cells are known as brown and beige fat. The study includes women with obesity and will last 24 weeks. Particip…
Phase: PHASE2 • Sponsor: University Medical Centre Ljubljana • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New trial matches cancer patients to smart drug bombs
Disease control Recruiting nowThis phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works in treating patients with solid…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to tackle returning myeloma
Disease control Recruiting nowThis phase I/II trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed). Immunothe…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for nigerian women with aggressive breast cancer: targeted drug combo under study
Disease control Recruiting nowDoctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment bef…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New study aims to wipe out aggressive breast cancer before surgery
Disease control Recruiting nowThe primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to i…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Liver cancer trial tests immunotherapy plus chemo combo
Disease control Recruiting nowTo evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could less radiation be just as good for some throat cancers?
Disease control Recruiting nowThis clinical trial tests the effect of induction chemotherapy response-guided radiation (de-escalated intensity-modulated radiation therapy \[IMRT\]) compared to standard IMRT in patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. Intensity-modulated radiati…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic drug aims to cut COPD attacks in half
Disease control Recruiting nowA Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for recurrent ovarian cancer: targeted drug combo enters human trials
Disease control Recruiting nowThe objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the RP2D of the combination, …
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug IMVT-1402 aims to stop CIDP relapses in Mid-Stage trial
Disease control Recruiting nowThis is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
Phase: PHASE2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Drones to the rescue: flying HIV meds to Uganda's islands
Disease control Recruiting nowThe goal of this clinical trial is to learn if the intervention of delivery of antiretroviral drugs by medical drones can improve virological suppression in a fisherfolk community population living with HIV in the islands of Kalangala District, Uganda. The main question it aims t…
Phase: NA • Sponsor: Makerere University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New shot helps diabetics shed pounds in major trial
Disease control OngoingThe primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Brain cancer breakthrough? new immunotherapy combo targets recurrent glioblastoma
Disease control Recruiting nowThe purpose of this study is to assess the safety and efficacy of the combination of D2C7-IT+2141-V11 administered in the non-enhancing tumor of patients with resected recurrent glioblastoma (rGBM) via convection enhanced delivery (CED), followed by subcutaneous cervical perilymp…
Phase: PHASE1 • Sponsor: Darell Bigner • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Wearable device could simplify multiple myeloma treatment
Disease control Recruiting nowThe primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lin…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a cholesterol drug boost lung cancer treatment before surgery?
Disease control TerminatedIn this open-label, two-arm, randomized phase 2 clinical trial, patients with clinical stage 1B-3A non-small cell lung cancer (NSCLC) will receive neoadjuvant chemotherapy and cemiplimab every 3 weeks for 3 cycles with or without alirocumab every 4 weeks prior to surgery. Eligib…
Phase: PHASE2 • Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug trial targets deadly inflammation in HIV patients
Disease control Recruiting nowBackground: Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS) and KSHV-multicentric Castleman disease (MCD) occur in people living with HIV. These diseases cause severe inflammation that can be fatal if not treated. Objective: To test a drug (p…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC